• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Exact Sciences Stock Could Sprint Higher in the Weeks Ahead

EXAS is likely to consolidate its recent gains.
By BRUCE KAMICH
Oct 08, 2020 | 09:00 AM EDT
Stocks quotes in this article: EXAS

For his final "Executive Decision" segment of  Mad Money Wednesday evening, Jim Cramer checked in Kevin Conroy, president, chairman and CEO of EXACT Sciences Corp. (EXAS) , makers of Cologuard, the colon cancer screening test that replaces traditional colonoscopies for some people.

Conroy said that cancer remains the second largest killer in our country, claiming 600,000 people a year. Yet despite those numbers, most people are still not tested for most cancers. That's why the early data from their multi-cancer screening test is so important. It can detect up to six cancers 84% of the time with very low false-positive rates.

Exact Sciences is also active in Covid-19 testing. Conroy said his company has tested hundreds of thousands of people in all 50 states and he couldn't be more proud of his team and the diagnostic industry which is stepping up to help their communities. 

 
Let's see what the charts of EXAS look like now.
 
In this updated daily bar chart of EXAS, below, we can see that prices made a white-knuckle decline from February to March but rebounded into late July. The July-September correction was not so deep to question the resumption of the rally. EXAS exploded higher in late September on heavy turnover. Prices surged above the popular moving averages to new 2020 highs.
 
The On-Balance-Volume (OBV) line also quickly climbed to a new high to confirm the price gains. The Moving Average Convergence Divergence (MACD) oscillator quickly turned from bearish to bullish. 
 
 
 
In this weekly bar chart of EXAS, below, we can see that prices are now poised to retest the highs of 2019 in the $120-$125 area. Prices are above the now rising 40-week moving average line.
 
The OBV line just made a new high over the highs of 2019 and 2020. Impressive. The MACD oscillator crossed above the zero line last month for a fresh outright buy signal. 
 
 
 
In this daily Point and Figure chart of EXAS, below, we can see that the software is projecting the $187 area as a potential price target. 
 
 
Bottom line strategy: EXAS is likely to consolidate its recent gains. I would anticipate some sideways trading in the $110-$100 area for a short period of time. Aggressive traders could use available weakness to go long risking a close below $95. The $187 area is our price objective. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Healthcare | Mad Money | Executive Interview

More from Investing

Could Johnson & Johnson Go Higher and Higher?

Ed Ponsi
Jan 26, 2021 10:00 AM EST

Will the vaccine will be a game changer? The charts are giving indications that J&J is ready to run.

Clorox Is Ready to Clean Up as the Downtrend Has Been Broken

Bruce Kamich
Jan 26, 2021 9:20 AM EST

Let's review the charts and indicators.

An Entertainment Giant and a Big Drugmaker Present Buy Setups

Carolyn Boroden
Jan 26, 2021 8:30 AM EST

The stocks of Walt Disney Co. and Pfizer seem to offer nice upside potential based on their technical patterns.

Boot Barn Is Kickin' It, but Wait for a Correction to Saddle Up

Bruce Kamich
Jan 26, 2021 8:07 AM EST

The indicators for the western apparel retailer are bullish, but prices are extended compared to the longer-term moving averages, so be cautious.

Youth Gone Wild, The Swarm of Individual Traders, GameStop, Melvin Capital

Stephen Guilfoyle
Jan 26, 2021 7:32 AM EST

As a trader who at times takes short positions, I don't know whether to stand up and applaud this group or to fear them.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • 08:05 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/26/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 09:52 AM EST GARY BERMAN

    INDU/DIA 20 DMA

    Fibocall: The DIA has the 20 DMA @ 307.81 and w...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login